Gemelli Biotech announced today that its diagnostic technologies will be featured across multiple research presentations at DDW 2026, the world's premier gathering of gastrointestinal researchers and ...

Biomerica, Inc. (Nasdaq: BMRA), a global biomedical technology company focused on innovative diagnostic-guided therapies, today announced that an abstract evaluating the real-world clinical ...

Biomerica, Inc. announced that the American Medical Association's CPT editorial panel has granted a Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, which personalizes the ...

Biomerica applies for a PLA code to enhance patient access to its inFoods IBS diagnostic test for personalized IBS management. Biomerica, Inc. has submitted an application to the American Medical ...

The inFoods ® IBS test is a novel, non-invasive diagnostic that identifies patient-specific IBS trigger foods that may be contributing to IBS symptoms such as bloating, abdominal pain, diarrhea, and ...

The Medicare Administrative Contractor (MAC) responsible for processing inFoods® IBS claims has confirmed to Biomerica’s certified laboratory partner that the test will be reviewed on an individual, ...

inFoods IBS Provides Personalized Diet Therapy for Patients Suffering with Irritable Bowel Syndrome (IBS) Research Finds Patients Following a Personalized Diet Therapy Created with inFoods ® IBS, ...

PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods ® IBS inFoods ...

Clinical study results show patients who eliminated foods as determined by the inFoods® IBS test experience significant improvement in IBS Symptoms Including Abdominal Pain Intensity (API) IRVINE, ...

inFoods IBS showed improvement in API similar to, and in some cases better than, current IBS drugs in the market NEWPORT BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA), ...